title: Dexmedetomidine improves the histological and neurological outcomes 48 h after transient spinal ischemia in rats.
abstract: Dexmedetomidine, an α2 adrenoceptor agonist, provides neuroprotection against various cerebral ischemia models through its anti-apoptotic effects. Dexmedetomidine also improves paraplegia induced by intrathecal morphine after short-term spinal ischemia. However, there are no reports regarding dexmedetomidine׳s ability to provide neuroprotection solely against transient spinal ischemia. We investigated whether dexmedetomidine would provide spinal protection following transient spinal ischemia in rats. Adult male Sprague Dawley rats were randomly assigned to one of the following five groups: (1) intravenous infusion of 0.9% NaCl at the rate of 0.5 mL/h (control), (2) dexmedetomidine 0.1 µg/kg/h, (3) dexmedetomidine 1 µg/kg/h, (4) dexmedetomidine 10 µg/kg/h, or (5) intravenous infusion of 0.9% NaCl without spinal ischemia (sham). The rats received saline solution or dexmedetomidine from 30 min before spinal cord ischemia to 48 h after ischemia. Spinal cord ischemia was induced by intraaortic balloon occlusion combined with proximal arterial hypotension for 10 min. Ischemic injury was assessed by neurological deficit scores and the number of viable motor nerve cells in the anterior spinal cord at 48 h after reperfusion. Neurological deficit scores in the dexmedetomidine-treated rats were significantly lower than the scores in the control group at 24 and 48 h after ischemia (P<0.05). The number of viable motor nerve cells was significantly larger in the dexmedetomidine-treated rats than in the control rats (P<0.05), but the number of motor nerve cells in the dexmedetomidine group was significantly smaller than the sham group. Our results indicate that the continuous administration of dexmedetomidine improves neurological and histological outcomes 48 h after transient spinal ischemia in rats.
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita-city, Akita, Japan. Electronic address: tgoyagi@doc.med.akita-u.ac.jp.
authors.forename: Toru
authors.initials: T
authors.lastname: Goyagi
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita-city, Akita, Japan.
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Tobe
mesh_terms: D000818:Animals; D020927:Dexmedetomidine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009046:Motor Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000473:pathology; D020760:Spinal Cord Ischemia / Q000188:drug therapy*
chemical_list: D018696:Neuroprotective Agents; D020927:Dexmedetomidine
keywords: Dexmedetomidine; Spinal ischemia; α(2)-Agonist